Northern Trust Corp Lowers Position in Integra LifeSciences Holdings Corporation $IART

Northern Trust Corp reduced its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 1.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 875,223 shares of the life sciences company's stock after selling 17,202 shares during the quarter. Northern Trust Corp owned 1.13% of Integra LifeSciences worth $19,246,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. lifted its position in shares of Integra LifeSciences by 2,418.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock valued at $39,581,000 after buying an additional 1,728,480 shares in the last quarter. Paradigm Capital Management Inc. NY lifted its position in shares of Integra LifeSciences by 170.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock valued at $32,457,000 after buying an additional 901,600 shares in the last quarter. Soleus Capital Management L.P. purchased a new position in shares of Integra LifeSciences during the 4th quarter valued at approximately $28,940,000. Charles Schwab Investment Management Inc. lifted its position in shares of Integra LifeSciences by 9.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,146,921 shares of the life sciences company's stock valued at $25,221,000 after buying an additional 99,348 shares in the last quarter. Finally, Systematic Financial Management LP lifted its position in shares of Integra LifeSciences by 40.7% during the 4th quarter. Systematic Financial Management LP now owns 860,563 shares of the life sciences company's stock valued at $19,518,000 after buying an additional 248,817 shares in the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Price Performance

Shares of IART traded up $0.27 during trading hours on Friday, hitting $15.92. 685,554 shares of the stock were exchanged, compared to its average volume of 1,048,424. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. Integra LifeSciences Holdings Corporation has a 12-month low of $11.06 and a 12-month high of $27.13. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -2.45, a price-to-earnings-growth ratio of 0.85 and a beta of 1.20. The stock's 50-day moving average price is $13.32 and its two-hundred day moving average price is $15.83.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. During the same period in the previous year, the business earned $0.63 earnings per share. The firm's revenue for the quarter was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

Separately, JMP Securities decreased their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Reduce" and an average target price of $18.43.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.